Kirill Eves is a visionary serial entrepreneur and founder, building successful industry-shaping fintech companies for over 15 years. His portfolio includes Unlimit.com, one of the largest global payment infrastructures, and Stable.com, USD3 and Blockchain settlement layer. An eminent investor with a nack for groundbreaking start-ups, he developed the concept of e184, an advanced research funding organisation, during his time at Stanford School of Business, while thinking up solutions to the task of accelerating the emergence of critically important technologies that would advance human evolution in his campus room numbered e184 (hence the name). Kirill is a relentless techno-optimist and dreamer.

Alex is responsible for executing e184's vision by turning it into an actionable strategy and overseeing its day-to-day operations. He's an investment professional with experience that includes Draper X (a VC firm led by the legendary Tim Draper) and running his own investment banking advisory boutique. To stay up-to-date with the trends in different industries in which he has been involved, Alex developed a taste for knowing what's happening in technology and science.

Peter leads neurotech practice at e184. He was previously an investment manager at 7percent Ventures, a London-based deep tech fund. During his career, Peter invested across the aerospace, transportation, and agriculture sectors and the data stack. As an angel/VC investor, Peter backed Beyond Aero, CoMind, Five AI, and QuestDB, among other things. Peter’s passion for neurotech was manifested in his writing and angel investing and eventually became his focus. When he's out of the office, you could find him at neuro conferences or smashed on the mats of a Brazilian jiu-jitsu academy.

Fernanda’s main focus at e184 is on assisted reproductive technologies (ART). Her background lies at the intersection of genetics, data, machine learning, and finance — a bit of everything. A deeply curious mind, constantly exploring innovative ways to leverage the power of science and data within the HealthTech space. Her main goal is to help transform these insights into tangible products aimed at addressing health threats by facilitating and pioneering life science‐based companies, where she can leverage her diverse background in various fields as tools for driving positive change in healthcare and life sciences.